A Phase 1 interventional study of Psilocybin in Short Lasting Unilateral Neuralgiform Headache Attacks, sponsored by Beckley Psytech Limited. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-10-12.
Sponsored by Beckley Psytech Limited (part of Eli Lilly and Company) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Headache by Eli Lilly and Company — none open to participants now, 2 under way, 2 of them phase 3. Headache · Eli Lilly and Company.
Among the 16 studies in Headache by Eli Lilly and Company, this one is the 16th largest by enrollment, is the only one that started in 2021, is one of 2 in phase 1, and was the 16th registered.
762 studies on the registry are indexed under Headache; 134 are open to participants now.
Browse Headache studies →None of the 16 studies in Headache by Eli Lilly and Company is open now. The open studies under Headache, anywhere →
Of the 83 Headache studies recruiting now, 30 (36%) set no upper age limit and 44 (53%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 65 across 560 interventional studies indexed under Headache.
Median enrollment 312 across the 16 interventional studies. Of the 14 that completed or were terminated, 13 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Beckley Psytech Limited, one of the names counted as Eli Lilly and Company. Under that name alone:
Beckley Psytech Limited is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Headache by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This exploratory open-label phase 1b, ascending dose study is to evaluate the effects of psilocybin on cognition in patients with Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)
The study aims to:
Determine the safety and tolerability of psilocybin when administered to patients with chronic SUNHA
Determine the effects of psilocybin on cognition when administered to patients with chronic SUNHA
Explore the change in frequency, duration, and intensity of headache attacks with escalating doses of psilocybin in patients with chronic SUNHA
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
* Diagnosed with chronic SUNHA
Exclusion Criteria:
* Other comorbidities
Drug: Psilocybin
Psilocybin will be provided in form of dry filled capsules and administered orally in three ascending doses
Percentage of patients with treatment emergent AEs (TEAES)
Time frame: From first dose administered through to the last follow up visit, approximately 39 days
Treatment-related changes in Paired Associates Learning (PAL) scores and evaluation of dose response
Time frame: From first dose administered until the las dose administered, approximately 11 days
Treatment-related changes in Spatial Working Memory (SWM) scores and evaluation of dose response
Time frame: From first dose administered until the las dose administered, approximately 11 days
Treatment-related changes in Reaction Time Index (RTI) scores and evaluation of dose response
Time frame: From first dose administered until the las dose administered, approximately 11 days
Treatment-related changes in Rapid Visual Information Processing (RVP) scores and evaluation of dose response
Time frame: From first dose administered until the las dose administered, approximately 11 days
Change in frequency of headache attacks
Time frame: From screening until the follow up visit, approximately 39 days
Change in duration of headache attacks
Time frame: From screening until the follow up visit, approximately 39 days
Change in intensity of headache attacks
Patients will complete a diary on a daily basis and capture the intensity of their headaches by assigning a score out of 10 where 0 is pain free and 10 is excruciating pain
Time frame: From screening until the follow up visit, approximately 39 days
Plan to share: No — Due to the UK GDPR, individual participant data will not be shared publicly. Group data will be presented in publication after study completion.
No publications or documents are linked to this record.
Ran from Aug 2021 to primary completion in Apr 2022, 8 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Psilocybin